BrainStorm Cell Therapeutics Inc.''s CEO Tony Fiorino Interviewed by The Life Sciences Report
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 05/21/15 -- An Israeli biotech is hard at work on a new treatment for neurodegenerative disease that holds promise in a variety of devastating diseases and enjoys fast-track and orphan drug status in its lead indication, amyotrophic lateral sclerosis (ALS). In Dr. Tony Fiorino, the U.S.-based CEO of (NASDAQ: BCLI), tells how his company is winning over American investors with a revolutionary, university lab-backed cell therapy.
BrainStorm Cell Therapeutics Inc. utilizes autologous stem cell therapies for neurodegenerative diseases, including ALS, multiple sclerosis (MS) and Parkinson''s disease. Please describe the origin of your patented treatment.
NurOwn is the trade name of our technology platform. It emerged from the neuroscience lab of Dani Offen and Eldad Melamed at Tel Aviv University. They were trying to differentiate mesenchymal stem cells (MSCs) into cells that could be active in the treatment of neurodegenerative diseases. They succeeded in identifying culture conditions that induced the MSCs to assume the phenotype of a neuronal support cell; in fact, they were called astrocyte-like cells in the early days of the company. We now refer to them as MSC-NTF cells, which is the shorthand for MSCs that are secreting neurotrophic factors (NTFs).
Do NurOwn cells have unique characteristics that differentiate them from other cell-based therapeutics undergoing clinical trials in the neurology space?
A lot of companies and academic institutions are working with MSCs, both autologous and allogeneic. MSCs are immunomodulatory, and that definitely plays a role...
Continue reading this interview with Tony Fiorino:
Investors rely on to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.
BrainStorm Cell Therapeutics Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Tony Fiorino had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Tony Fiorino and not of The Life Sciences Report or its officers.
Carrie Beal Amaro
Phone: 707-283-0676
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.05.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 1360551
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BrainStorm Cell Therapeutics Inc.''s CEO Tony Fiorino Interviewed by The Life Sciences Report
"
steht unter der journalistisch-redaktionellen Verantwortung von
Streetwise Reports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
